{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:28:54Z","timestamp":1787758134804,"version":"build-2784847793"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Presentation with symptoms of advanced prostate cancer is prevalent in developing societies. The objective of this study was to determine the rate of and factors associated with skeletal-related events (SREs) at presentation with hormone-na\u00efve prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Records of 331 consecutive prostate cancer patients from January 2009 to April 2018 were reviewed. The prevalence of SRE at the presentation was determined. In addition, the relationships between SRE and age of patient, duration of clinical features, serum total prostate-specific antigen (tPSA) and biopsy Gleason score (GS) at presentation were evaluated. Analyses were done with IBM SPSS\u00ae version 25.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Mean age was 69.8 \u00b1 8.0 years. While 43.8% of patients had lower urinary tract symptoms (LUTS) only, 51.4% had LUTS and other features of disease progression. Only 2.1% of the cases were confirmed from screen detection of elevated serum tPSA. SREs were observed in 11.8% at first presentations with hormone-na\u00efve prostate cancer. Symptom duration (odds ratio [OR] 0.94; 95% confidence interval [CI] 0.90\u20130.99;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02), anaemia that could not be attributed to gross haematuria or external blood loss (OR 9.6; 95% CI 3.12\u201329.52;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and transrectal biopsy GS (OR 1.61; 95% CI 1.17\u20132.22;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003) were significantly associated with SREs at presentation with hormone-na\u00efve prostate cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Evidence exists that patients who present with SREs from more aggressive prostate cancers may have had more rapid symptom progression, but not a longer delay before presentation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/npmj.npmj_70_22","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T02:06:44Z","timestamp":1658714804000},"page":"268-271","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence of Skeletal-Related Events in Hormone-naive Prostate Cancer in a Low Resource Setting"],"prefix":"10.4103","volume":"29","author":[{"given":"Fredrick Obiefuna","family":"Ugwumba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikenna Ifeanyi","family":"Nnabugwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agharighom David","family":"Okoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Ndubuisi","family":"Echetabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okechukwu","family":"Onwuasoigwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekeoma Okey","family":"Nwosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20240908","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jamaoncol.2018.2706","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study","volume":"4","author":"Fitzmaurice","year":"2018","journal-title":"JAMA Oncol"},{"key":"R2-14-20240908","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.canep.2016.04.014","article-title":"Five year cancer incidence in Calabar, Nigeria (2009-2013)","volume":"42","author":"Ekanem","year":"2016","journal-title":"Cancer Epidemiol"},{"key":"R3-14-20240908","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/j.canep.2012.04.007","article-title":"Cancer incidence in Nigeria: A report from population-based cancer registries","volume":"36","author":"Jedy-Agba","year":"2012","journal-title":"Cancer Epidemiol"},{"key":"R4-14-20240908","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/1115-2613.278256","article-title":"Pattern of prostate cancer among a Nigerian population: A study in a single tertiary care centre","volume":"25","author":"Adewumi","year":"2016","journal-title":"Niger J Med"},{"key":"R5-14-20240908","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jjco\/hyw034","article-title":"Urologic cancer in China","volume":"46","author":"Pang","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"R6-14-20240908","first-page":"70","article-title":"Clinico-pathological features of prostate cancer at the University Hospital Yalgado Ouedraogo, Ouagadougou, Burkina Faso","volume":"4","author":"Kirakoya","year":"2014","journal-title":"J West Afr Coll Surg"},{"key":"R7-14-20240908","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3892\/ol.2013.1372","article-title":"A new emergency in oncology: Bone metastases in breast cancer patients (Review)","volume":"6","author":"Ibrahim","year":"2013","journal-title":"Oncol Lett"},{"key":"R8-14-20240908","doi-asserted-by":"crossref","first-page":"54","DOI":"10.17159\/2078-5151\/2018\/v56n2a2324","article-title":"Investigating racial differences in clinical and pathological features of prostate cancer in South African men","volume":"56","author":"Dewar","year":"2018","journal-title":"S Afr J Surg"},{"key":"R10-14-20240908","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/AJM.AJM_19_20","article-title":"High mortality risk of prostate cancer patients in Asia and West Africa: A systematic review","volume":"10","author":"Okoye","year":"2020","journal-title":"Avicenna J Med"},{"key":"R11-14-20240908","doi-asserted-by":"crossref","first-page":"465","DOI":"10.5489\/cuaj.117","article-title":"Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice","volume":"6","author":"So","year":"2012","journal-title":"Can Urol Assoc J"},{"key":"R12-14-20240908","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(14)70303-1","article-title":"Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: Results from the randomised, phase 3 AFFIRM trial","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol"},{"key":"R13-14-20240908","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.urology.2010.03.020","article-title":"Burden of prostate cancer in southwestern Nigeria","volume":"76","author":"Badmus","year":"2010","journal-title":"Urology"},{"key":"R14-14-20240908","doi-asserted-by":"crossref","first-page":"1785428","DOI":"10.1155\/2019\/1785428","article-title":"Management of advanced and metastatic prostate cancer: A need for a Sub-Saharan guideline","volume":"2019","author":"Cassell","year":"2019","journal-title":"J Oncol"},{"key":"R15-14-20240908","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/CCO.0000000000000071","article-title":"Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer","volume":"26","author":"Yong","year":"2014","journal-title":"Curr Opin Oncol"},{"key":"R16-14-20240908","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00520-014-2437-3","article-title":"Burden of skeletal-related events in prostate cancer: Unmet need in pain improvement","volume":"23","author":"Broder","year":"2015","journal-title":"Support Care Cancer"},{"key":"R17-14-20240908","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10198-015-0716-7","article-title":"Health resource utilization associated with skeletal-related events: Results from a retrospective European study","volume":"17","author":"Body","year":"2016","journal-title":"Eur J Health Econ"},{"key":"R18-14-20240908","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1586\/era.10.136","article-title":"Burden of metastatic bone disease from genitourinary malignancies","volume":"10","author":"Mulders","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"R19-14-20240908","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1038\/s41598-020-63302-2","article-title":"Clinical aspects of mCRPC management in patients treated with radium-223","volume":"10","author":"Rizzini","year":"2020","journal-title":"Sci Rep"},{"key":"R20-14-20240908","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.semnuclmed.2019.11.005","article-title":"Radium-223 as an approved modality for treatment of bone metastases","volume":"50","author":"Brito","year":"2020","journal-title":"Semin Nucl Med"},{"key":"R21-14-20240908","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ucl.2021.04.004","article-title":"Basic science and molecular genetics of prostate cancer aggressiveness","volume":"48","author":"Schiewer","year":"2021","journal-title":"Urol Clin North Am"},{"key":"R22-14-20240908","doi-asserted-by":"crossref","first-page":"396","DOI":"10.4103\/0377-4929.138728","article-title":"The prognostic significance of bone marrow metastases: Evaluation of 58 cases","volume":"57","author":"Kucukzeybek","year":"2014","journal-title":"Indian J Pathol Microbiol"}],"container-title":["Nigerian Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/npmj.npmj_70_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:06:35Z","timestamp":1787756795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/npmj.npmj_70_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/npmj.npmj_70_22","relation":{},"ISSN":["1117-1936"],"issn-type":[{"value":"1117-1936","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}